RxDoctor Payments Data

Fatima Fayyaz, MD

Hematology & Oncology · Marmora, NJNPI 1962922658

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,019 of the $1,197 with a category attached, or 85.1%. It is spread thinly across 29 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $602, 4.0 times the $152 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.

$1,197in general payments, 2019–2025

Across 49 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$145
  • Novartis$128
  • Takeda Pharmaceuticals U.S.A., Inc.$121
  • Seagen Inc.$78
  • Exelixis Inc.$77
  • Johnson & Johnson$74
  • plus $575 from 23 others

What the payments were for

  • Food & beverage$1,01985%
  • Education$17815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,197 in reported general payments places this provider in the 35th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$109,219
Medicare patients
173
Services billed
11,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Marmora

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →